The Value of Prevention: Experiences of a Public Health Agency

Fryback DG. Reflections on the beginnings and future of Medical Decision Making. Med Decis Making. 2001; 21: 71–3.

Sencer DJ , Axnick NW. Utilization of cost/benefit analysis in planning prevention programs. Acta Med Scand. 1975; 576(Suppl): 123–9.

Sonnenberg FA. A look back—and ahead. Med Decis Making. 2001; 21: 69–70.

Beck JR. Medical decision making: 20 years of advancing the field. Med Decis Making. 2001; 21: 73–5.

Elstein A. The Society for Medical Decision Making at 21. Med Decis Making. 2001; 21: 75–7.

Pauker SG. A society for medical decision making. Med Decis Making. 2001; 21: 78–9.

Willems JS , Sanders CR. Cost-effectiveness and cost-benefit analyses of vaccines. J Infect Dis. 1981; 144: 486–93.

Sencer DJ , Axnick NW. Cost benefit analysis. International Symposium on Vaccination against Communicable Diseases, Monaco 1973. Symp Series Immunobiol Standard. 1973; 22:37–46.

Meltzer MI , Damon I , LeDuc JW , Millar JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis. 2001; 7: 948–58.

Koplan JP , Schoenbaum SC , Weinstein MC , Fraser DW. Pertussis vaccine—an analysis of benefits, risks, and costs. N Engl J Med. 1979; 301: 906–11.

Hinman AR , Koplan JP. Pertussis and pertussis vaccine: reanalysis of benefits, risks, and costs. JAMA. 1984; 251: 3109–13.

Koplan JP , Hinman AR. Decision analysis, public policy, and pertussis: are they compatible? Med Decis Making. 1987; 7: 71–3.

Koplan JP. The use of cost-effectiveness analyses at a federal public health agency. Drug Information J. 1988; 22: 407–10.

Roper WL , Winkenwerder W , Hackbarth GM , Krakauer H. Effectiveness in health care: an initiative to evaluate and improve medical practice. N Engl J Med. 1988; 316: 1197–202.

Teutsch SM. A framework for assessing the effectiveness of disease and injury prevention. MMWR Morb Mortal Wkly Rep. 1992; 41(No.RR-3): i–iv, 1-12.

Thacker SB , Koplan JP , Taylor WR , Hinman AR , Katz MF , Roper WL. Assessing prevention effectiveness using data to drive program decisions. Public Health Rep. 1994; 109: 187–94.

Haddix AC , Teutsch SM , Corso PS , editors. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. 2nd ed. New York: Oxford University Press; in press.

Thacker SB , Dannenberg AL , Hamilton DH. Epidemic Intelligence Service of the Centers for Disease Control and Prevention: 50 years of training and service in applied epidemiology. Am J Epidemiol. 2001; 154: 985–92.

Gold MR , Siegel JE , Russell LB , Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.

Centers for Disease Control and Prevention. Cigarette smoking-attributable mortality and years of potential life lost—United States, 1990. MMWR Morb Mortal Wkly Rep. 1993; 42: 645–9.

Rice DP , Hodgson TA. The economic costs of the health effects of smoking. Milbank Q. 1986; 64: 489–547.

Hodgson TA. Cigarette smoking and lifetime medical expenditures. Milbank Q. 1992; 70: 81–125.

Hopkins DP , Briss PA , Ricard CJ Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med. 2001; 20(2S): 16–66.

Orme ME , Hogue SL , Kennedy LM , Paine AC , Godfrey C. Development of the health and economic consequences of smoking interactive model. Tob Control. 2001; 10: 55–61.

Chaloupka FJ , Cummings KM , Morley CP , Horan JK. Tax, price and cigarette smoking: evidence from the tobacco documents and implications for tobacco company marketing strategies. Tob Control. 2002; 11(S1): i62–72.

US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Alexandria, VA: International Medical Publishing; 1996.

Zaza S , Wright-De Aguero LK , Briss PA Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services. Am J Prev Med. 2000; 18(1S): 44–74.

Carande-Kulis VG , Maciosek MV , Briss PA Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Am J Prev Med. 2000; 18(1S): 75–91.

Briss PA , Rodewald LE , Hinman AR Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med. 2000; 18(1S): 97–140.

Shultz RA , Elder RW , Sleet DA Reviews of evidence regarding interventions to reduce alcohol-impaired driving. Am J Prev Med. 2001; 21(4S): 66–88.

Norris SL , Nichols PJ , Casperson CJ The effectiveness of disease and case management for people with diabetes: a systematic review. Am J Prev Med. 2002; 22(4S): 15–38.

Kahn EB , Ramsey LT , Brownson RC The effectiveness of interventions to increase physical activity: a systematic review. Am J Prev Med. 2002; 22(4S): 73–107.

Phillips KA , Holtgrave DR. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention? Am J Prev Med. 1997; 13: 18–25.

Cretin S. Cost/benefit analysis of treatment and prevention of myocardial infarction. Health Serv Res. 1977: 174–89.

Carr-Hill RA. Allocating resources to health care: is the QALY (quality adjusted life year) a technical solution to a political problem? Int J Health Services. 1991; 21: 351–63.

Ubel PA , Spranca MD , DeKay ML , Hershey JC , Asch DA. Public preferences for prevention versus cure: what if an ounce of prevention is worth only an ounce of cure? Med Decis Making. 1998; 18: 141–8.

Jenni KE , Loewenstein G. Explaining the “identifiable victim effect.” J Risk Uncertain. 1997; 14: 235–57.

Eddy DM. The individual vs society: is there a conflict? JAMA. 1991; 265: 1446–50.

Eddy DM. The individual vs society: resolving the conflict. JAMA. 1991; 265: 2399–406.